Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00006089 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenocarcinoma
ERBB2 Gene Amplification
Recurrent Uterine Corpus Carcinoma
Stage III Uterine Corpus Cancer AJCC v7
Stage IV Uterine Corpus Cancer AJCC v7

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Trastuzumab

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]